Prognostic Predictors of Response to Hypoglycemic Therapy

What this study is testing ClinicalTrials.gov NCT03804411 ↗

Description as written by the study sponsor.

This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.

Treatments tested

• Automatic system guided treatment Drug

  Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide

• Standard treatment Drug

  Addition of: 1. B -vildagliptin 100 mg/day 2. B - sitagliptin 100 mg/day, 3. B- dapagliflozin 10 mg/day 4. B- empagliflozin 10 mg/day 5. B- liraglutide 1,2-1,8 mg/day 6. B- exenatide 20 μg/day 7. B - glimepiride 8. B - gliclazide